Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash from Investing Activities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Cash from Investing Activities for 8 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 398.93% year-over-year to $5.7 million, compared with a TTM value of $9.6 million through Sep 2025, up 141.31%, and an annual FY2024 reading of -$22.7 million, changed N/A over the prior year.
  • Cash from Investing Activities was $5.7 million for Q3 2025 at Kiora Pharmaceuticals, up from $664172.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $5.7 million in Q3 2025 and bottomed at -$21.2 million in Q2 2024.
  • Average Cash from Investing Activities over 5 years is -$1.2 million, with a median of -$5746.0 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 332839.67% in 2024, then skyrocketed 398.93% in 2025.
  • Year by year, Cash from Investing Activities stood at -$93155.0 in 2021, then skyrocketed by 106.84% to $6375.0 in 2022, then tumbled by 200.0% to -$6375.0 in 2023, then soared by 7671.5% to $482683.0 in 2024, then surged by 1089.3% to $5.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for KPRX at $5.7 million in Q3 2025, $664172.0 in Q2 2025, and $2.7 million in Q1 2025.